Literature DB >> 10081287

[Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

P P Nawroth1, A Bierhaus, G E Vogel, M A Hofmann, M Zumbach, P Wahl, R Ziegler.   

Abstract

UNLABELLED: New approaches in biochemistry and molecular biology have increased the knowledge on the pathophysiology of chronic diseases as late diabetic complications, Alzheimer's disease, arteriosclerosis and vascular disease by defining the concept of "AGE-formation and oxidative stress." Nonenzymatic glycation, in which reducing sugars are covalently bound to free aminogroups of macromolecules, results in the formation of Advanced Glycation End products (AGEs) which accumulate during aging and at accelerated rate during the course of diabetes. Glycation accompanying oxidation processes support AGE-formation. AGE-formation changes the physicochemical properties of proteins, lipids and nucleic acids. In addition, binding of AGEs to specific surface receptors induces cellular signalling and cell activation. Interaction of AGEs with one of the receptors, RAGE, generates intracellular oxidative stress, which results in activation of the transcription factor NF-kappa B and subsequent gene expression, which might be relevant in late diabetic complications.
CONCLUSION: Knowledge of the basis molecular mechanisms allows to understand the interplay of different inducers such as redicals, cytokines, AGE-proteins and amyloid-beta-peptids and to define oxidative stress as a "common endpoint" of cell dysfunction. With respect to therapeutic options it is now possible not only to optimize blood glycemic control, but also to design drugs such as AGE-inhibitors and AGE-"cross-link" breakers. In addition patients with chronic disease associated with increased oxidative stress ay benefit from an antioxidant rich (and AGE protein poor?) nutrition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081287     DOI: 10.1007/bf03044692

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  139 in total

1.  Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats.

Authors:  S Yagihashi; M Kamijo; M Baba; N Yagihashi; K Nagai
Journal:  Diabetes       Date:  1992-01       Impact factor: 9.461

Review 2.  [Accumulation of AGE (advanced glycosylation end-products) in the aging process, in diabetes mellitus and in chronic renal failure].

Authors:  J Wisotzky; M Sommer; K Schubert; G Stein
Journal:  Med Klin (Munich)       Date:  1996-07-15

3.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

4.  Purification and partial amino acid sequencing of a fructosyllysine-specific binding protein from cell membranes of the monocyte-like cell line U937.

Authors:  S Krantz; R Salazar; R Brandt; J Kellermann; F Lottspeich
Journal:  Biochim Biophys Acta       Date:  1995-04-06

5.  Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex.

Authors:  H Vlassara; Y M Li; F Imani; D Wojciechowicz; Z Yang; F T Liu; A Cerami
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

6.  Hydrogen peroxide production during experimental protein glycation.

Authors:  Z Y Jiang; A C Woollard; S P Wolff
Journal:  FEBS Lett       Date:  1990-07-30       Impact factor: 4.124

Review 7.  Advanced glycation end-products and atherosclerosis.

Authors:  H Vlassara
Journal:  Ann Med       Date:  1996-10       Impact factor: 4.709

Review 8.  Advanced glycation endproducts and diabetic nephropathy.

Authors:  Z Makita; K Yanagisawa; S Kuwajima; N Yoshioka; T Atsumi; Y Hasunuma; T Koike
Journal:  J Diabetes Complications       Date:  1995 Oct-Dec       Impact factor: 2.852

9.  Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  Diabetes       Date:  1988-04       Impact factor: 9.461

10.  The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins.

Authors:  B S Lewis; J J Harding
Journal:  Exp Eye Res       Date:  1990-05       Impact factor: 3.467

View more
  6 in total

1.  The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis.

Authors:  Gert E Hein; Markus Köhler; Peter Oelzner; Günter Stein; Sybille Franke
Journal:  Rheumatol Int       Date:  2004-12-03       Impact factor: 2.631

2.  Antioxidant and antiglycation properties of triterpenoid saponins from Aralia taibaiensis traditionally used for treating diabetes mellitus.

Authors:  Miaomiao Xi; Chunxu Hai; Haifeng Tang; Aidong Wen; Hongli Chen; Rui Liu; Xin Liang; Mingsheng Chen
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

3.  Association of polymorphisms of the receptor for advanced glycation end products gene with COPD in the Chinese population.

Authors:  You Li; Cheng Yang; Guoda Ma; Xuefeng Gu; Min Chen; Yanyan Chen; Bin Zhao; Lili Cui; Keshen Li
Journal:  DNA Cell Biol       Date:  2014-02-12       Impact factor: 3.311

4.  Age-dependent accumulation of advanced glycation endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine.

Authors:  A Georgescu; D Popov
Journal:  J Am Aging Assoc       Date:  2000-01

Review 5.  Redox signaling in cardiovascular pathophysiology: A focus on hydrogen peroxide and vascular smooth muscle cells.

Authors:  Chang Hyun Byon; Jack M Heath; Yabing Chen
Journal:  Redox Biol       Date:  2016-08-26       Impact factor: 11.799

6.  N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.

Authors:  Khaled A Ahmed; Sekaran Muniandy; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.